Enhertu granted FDA priority review for HER2-positive breast cancer
AstraZeneca and Daiichi Sankyo are seeking approval for Enhertu in people with residual disease after HER2-targeted therapy before surgery.
News
-
-
Inflammatory diet associated with higher breast cancer risk
A recent review showed that eating more inflammatory foods is significantly associated with increased breast cancer risk.
-
Minorities underrepresented in clinical trials for breast cancer
Researchers say improving inclusion will require coordinated changes in how studies are designed, explained and made accessible.
-
Hypertension management linked to better survival in metastatic breast cancer
Treating hypertension with polytherapy was tied to a 38% lower risk of death from any cause in women with metastatic breast cancer.
-
First patient dosed in clinical trial for HER2-positive breast cancer
Innovent Biologics has dosed the first patient in their Phase 3 HeriCare-Breast01 trial of IBI354 in HER2-positive breast cancer.
-
Alcohol consumption linked to increased breast cancer risk
A recent study showed alcohol consumption is associated with an increased risk of breast cancer and poorer overall survival outcomes.
-
Immunotherapy improves survival in some types of breast cancer
Immunotherapy can improve the chance of tumor disappearance before surgery and may extend survival in certain high-risk groups.
-
Review: 10 recently approved oncology drugs improve patient outcomes
The review highlighted how recent advancements in oncology drugs and therapies have led to better outcomes for patients.
-
Pilates and dance may improve arm function after breast cancer surgery
A randomized trial found that both Mat Pilates and belly dance programs led to significant gains in arm strength after breast cancer surgery.
-
Black women with metastatic breast cancer face delays in care
Black patients with HR+, HER2 negative metastatic breast cancer were less likely to receive recommended therapy and had shorter survival.